Pierre Fenaux
Led AZA-001, which showed azacitidine extends survival in high-risk MDS and made hypomethylating agents standard.
Overview
Pierre Fenaux (Hôpital Saint-Louis, Paris) was principal investigator of AZA-001, the trial that showed azacitidine improves overall survival compared with conventional care in higher-risk myelodysplastic syndromes, the first drug to do so and the foundation of hypomethylating therapy in MDS and AML. He co-led the European APL trials with Laurent Degos that established all-trans retinoic acid and leads the Groupe Francophone des Myélodysplasies.
| Title | Journal | Year |
|---|---|---|
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (AZA-001) | Lancet Oncology | 2009 |
| Myelodysplastic syndromes | Lancet | 2014 |
Pages like this
not linked directly; found by shared links- PersonUwe Platzbecker
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag mds.
- PersonMarc H.G.P. Raaijmakers
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- ProductDecitabine
Shares Myelodysplastic syndromes / neoplasms (MDS), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- ProductDorocubicel (UM171-expanded cord blood)
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TermHypomethylating agents (azacitidine, decitabine)
Shares Myelodysplastic syndromes / neoplasms (MDS), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- PersonChristopher R. Vakoc
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
- ProductTreosulfan
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- InstitutionUSC Norris Comprehensive Cancer Center
Shares Myelodysplastic syndromes / neoplasms (MDS), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.